FDA Roundup: October 18, 2024
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
NovoCure Scoops FDA Approval on Wearable for Metastatic Cancer Treatment
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $28
Hong Kong Stock Market News | Zai Lab (09688) rose more than 4%. Novocure's tumor electric field treatment Optune Lua has been approved by the FDA for lung cancer treatment.
zai lab (09688) rose more than 4%, as of the press release, up 4.06%, at 20.25 Hong Kong dollars, with a turnover of 25.3939 million Hong Kong dollars.